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Introduction: Pain is often reported as being the worst aspect of orthodontic treatment. 
Nearly all patients experience pain and discomfort at their teeth at some point during 
orthodontic treatment. Little information exists on the severity of pain in the latter stages 
of orthodontic treatment. In addition, no studies have investigated the role of genetic 
factors on pain caused by fixed appliances.  
 
Objectives: To investigate whether demographic, clinical or genetic factors are associated 
with the severity of pain experienced following adjustment of fixed orthodontic appliances.  
 
Methods: Eighty-two participants undergoing fixed orthodontic treatment were recruited. 
Baseline DNA was collected via blood or saliva samples. Immediately after bond-up or an 
adjustment of the fixed appliances, the participants used a smartphone app to record 
regular pain scores at their teeth over the following three days. 
 
Results: Pain peaked approximately 19 hours after the orthodontic adjustment, then 
gradually returned toward baseline levels by day three. Pain on chewing was significantly 
greater than the resting pain at the teeth at all time points concerned. There was a 
significant difference in the total amount of pain at the teeth over the three days when 
comparing bond-ups to no arch wire changes (with or without bends placed). Gender, age, 
and time in treatment were not associated with the severity of pain experienced after an 
orthodontic adjustment. The rs931233 SNP of the HTR2A and the rs4646310 SNP of the 
COMT genes were significantly associated with pain severity. Haplotypes of the COMT 
gene also showed promising, although non-significant associations with pain severity.  
 
Conclusions: Pain on chewing is significantly more painful compared to resting pain at the 
teeth after adjustment of fixed appliances. SNPs of the HTR2A and COMT gene were 
associated with the severity of pain following adjustment of fixed appliances. Therefore, it 
seems that genetic factors have a modifying effect on orthodontic pain (as is the case with 
many other pain conditions such as TMD, fibromyalgia, and experimental pain). Larger 




This research project focuses primarily on the clinical and genetic factors associated with 
orthodontic pain, and is divided into five main chapters that are organised as follows:  
 
Chapter 1 – General introduction and review of the literature  
A general overview of orthodontic pain and the genetics associated with various pain 
conditions are presented in the first chapter. This introductory chapter includes a review 
of the mechanism of orthodontic pain, the effect that pain has on patients, and the variables 
that are known to affect it. In addition, the genetics section focuses on the specific genetic 
factors associated with temporomandibular disorder, as well as the structure and 
physiology of the COMT gene and enzyme, one of the most commonly studied pain genes.  
 
Chapter 2 – Core methods and materials 
The methodological details of the present work are presented in the second chapter. The 
chapter covers aspects of study design, patient recruitment, app development and 
experimental procedure.  
 
Chapter 3 – Ecological momentary assessment of pain profiles in adolescents undergoing 
orthodontic treatment 
The orthodontic pain profile and limitations associated with previous pain research in 
orthodontics are briefly described. The methods section of this chapter includes a 
description of the specific methods used to measure and analyse pain at the teeth in the 
first three days following an orthodontic adjustment. Findings from this analysis are 
presented and discussed.  
 
Chapter 4 – Genetic factors associated with orthodontic pain in adolescents 
The role of genetic factors on TMD and general pain conditions are described briefly. The 
methods section of this chapter includes a description of the specific methods used in DNA 
collection and analysis. Finally, the findings of the genetic and pain analysis are presented 





Chapter 5 – Conclusions and future directions 
The fifth and final chapter of this work highlights the study’s conclusions and the exciting 
avenues that could be investigated in the future.  
 
Chapter 6 – References 
 
Chapter 7 - Appendices 
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1. Literature review 
	
1.1 Introduction 
Orthodontic treatment can bring many positive benefits for patients, including 
improvements in dental appearance, facial appearance, and psychological well-being (Proffit 
et al., 2014). However, there are also several adverse effects of orthodontic treatment 
which patients must endure. Many patients report pain as being the worst aspect of 
orthodontic treatment (Oliver and Knapman, 1985). Pain is surprisingly common, with 
more than 90% of patients experiencing pain and discomfort at some point during their 
orthodontic treatment (Scheurer et al., 1996; Erdinc and Dinçer, 2004). It has been 
reported that the pain experienced following placement of an initial arch wire is usually 
more severe, and lasts for longer than the pain following premolar extractions (Jones and 
Chan, 1992). It is therefore not surprising that early pain experiences can trigger a small 
proportion of patients (8%) to discontinue their orthodontic treatment prematurely (Patel, 
1989). Orthodontic fixed appliances have also been shown to reduce patients’ oral health-
related quality of life (OHRQoL) for a period of about one month following their insertion. 
Reasons for the reduction in OHRQoL included physical pain, psychological discomfort, 
and physical disability (Chen et al., 2010).  
	
1.2 Definitions of pain and discomfort 
The International Association for the Study of Pain defines pain as “an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage, or described 
in terms of such damage” (Mersky and Bodguk, 1994). Pain functions as a warning signal, 
to alert the organism to tissue damage, thereby enabling the organism to avoid harm 
(Bergius et al., 2000). Discomfort is defined as “slight pain” (Oxford Dictionary, 2015). 
According to their definitions, pain and discomfort are simply two points on the same 
continuum. It stands to reason that discomfort is a mild form of pain, and that these two 






1.3 Mechanism of orthodontic pain  
The act of applying forces to a tooth surface often results in pain which can be categorised 
as either an immediate or a delayed response. The immediate pain response is due to the 
compression of the periodontal ligament (PDL), while the delayed response is attributed 
to hyperalgaesia of the PDL (Burstone, 1962). The application of orthodontic forces on 
teeth can cause pressure, ischaemia, inflammation and oedema in the PDL space, which 
ultimately results in pain (Furstman and Bernick, 1972). The mechanical forces on the teeth 
cause an acute inflammatory reaction within the PDL, leading to vasodilation and the 
release of inflammatory mediators. These inflammatory mediators are responsible for the 
hyperalgaesia, causing the PDL to become more sensitive to pain (Yamasaki et al., 1984; 
Shanfeld et al., 1986; Nicolay et al., 1990; Saito et al., 1991; Vandevska-Radunovic, 1999). 
Thus, the PDL becomes more sensitive to algogens (pain-causing chemicals) like substance 
P, histamine, prostaglandin E, serotonin and bradykinin (Ferreira et al., 1978; Polat et al., 
2005).  
    
These algogens then stimulate the afferent A-δ and C nerve fibres of the trigeminal nerve. 
Both the trigeminal nerve and the trigeminal nucleus caudalis are involved in processing 
orofacial sensory information (Krishnan, 2007). Action potentials from the first-order 
afferents enter the dorsal roots of the spinal cord and synapse with second-order neurons. 
The second-order neurons then ascend in the anterolateral tract and synapse with the 
third-order neurons in the thalamic nuclei. There are two nociception pathways: fast 
physiologic pain is conducted by the neospinothalamic system, while slow pathologic pain 
is conducted via the paleospinothalamic system (Skjelbred and Lökken, 1997). The third-
order neurons in the thalamus then run to the cerebral cortex, where the pain is 
interpreted, and an appropriate response is prepared.  
    
Neurons also play a part in the pain process. When afferent neurons are stimulated by an 
inflammatory reaction, there is an antidromic release of neuropeptides, which results in 
further inflammation. This process is known as “neurogenic inflammation” (Vandevska-
Radunovic, 1999). Neuropeptides such as neurofilament protein (NFP), calcitonin gene-
related peptide (CGRP), vasoactive intestinal polypeptide (VIP), neuropeptide Y (NPY), 
and substance P (SP) have all been implicated in this process. SP, released from sensory 
peripheral nerve endings, causes monocytes to secrete cytokines like interleukin-1β (IL-1β), 
IL-6 and tumour necrosis factor-α (TNF-α), which elicit acute or chronic inflammation, as 
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well as bone resorption (Nicolay et al., 1990; Norevall et al., 1995). In support of this 
theory, markedly increased levels of IL-1 and TNF have been found in the PDL and alveolar 
bone cells of cat canines which had been moved orthodontically (Davidovitch et al., 1988; 
Davidovitch, 1991). These biochemical mediators are also released in the gingival crevicular 
fluid of humans following the placement of elastic separators. Interestingly, the intensity of 
pain one hour after placement of separators was correlated with the levels of prostaglandin 
E2, while the intensity of pain one day following placement of separators was associated 
with IL-β2 levels (Giannopoulou et al., 2006).	
	
1.4 Impact of pain and discomfort on jaw function 
There have been several studies which have investigated the onset of pain following the 
application of fixed appliances. It is generally accepted that pain begins a few hours after an 
orthodontic force is applied, peaks around 24 hours, lasts for between three to five days, 
and returns to baseline levels after about seven days (Ngan et al., 1989; Jones and Chan, 
1992).  
    
After 24 hours, 94% of patients reported pain from their orthodontic appliances 
(transpalatal arch, partial appliances, upper and/or lower fixed appliances). For those 
reporting pain, a mean pain score of 42 out of 100 (range of 0-100, no standard deviation 
given) on the visual analogue scale (VAS) has been reported (Scheurer et al., 1996). 
Therefore, orthodontic pain caused by fixed appliances can be regarded as significant, and 
of moderate intensity for the average patient. During orthodontic treatment, patients 
describe feeling tension, pressure, soreness of teeth, and pain. The most severe pain is 
induced by incising and chewing food, with VAS scores approaching 50-55 as early as four 
hours following the placement of an initial arch wire (Ngan et al., 1989). Because of the 
pain evoked during incising and chewing, many patients struggle to bite and chew food of 
a firm or hard consistency. As a result, these patients are forced to change the consistency 
of their diet for a few days (Krishnan, 2007). 
    
In addition, studies have demonstrated that orthodontic pain arising from the periodontal 
nociceptors can effect changes in motor neuron output, which results in a decrease in the 
activity of jaw-closing muscles such as the masseter and temporalis. It is hypothesised that 
these changes are mediated in the brain stem, and act as a protective mechanism to prevent 
further damage to the injured part of the masticatory system (Goldreich et al., 1994; 
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Michelotti et al., 1999). 
    
It is believed that patients adapt to the continuous pain and discomfort of orthodontic 
treatment, because the sensations soon cease or disappear from their focus of attention 
(Gosney, 1985; Jones and Chan, 1992). Indeed, the pain experienced from fixed appliances 
has been shown to cause disturbances in a patient’s sleep pattern immediately after 
placement, with significant improvements over the following days (Scheurer et al., 1996). 
One explanation for this observation is that patients adapt to their new appliances within 
the first seven days, with most patients reporting significant decreases in the amount of 
perceived pressure, tension, sensitivity of teeth, and pain, after as little as three to five days 
following the insertion of appliances. Assuming that forces stay relatively constant within 
the first seven days of appliance insertion, the adaptation to pain and discomfort may be 
due to changes in perception of adverse stimulation by the patients (Sergl et al., 1998).  
	
1.5 Variables that affect orthodontic pain 
1.5.1 Sociodemographic variables 
There is a huge variation in pain response among individuals undergoing orthodontic 
treatment. Some patients experience high levels of pain, while others experience only mild 
discomfort (Ngan et al., 1989; Bergius et al., 2008). The sensory reaction to pain is complex, 
partly because pain is modulated by the higher centres of the nervous system (Polat, 2007). 
    
The vast majority of studies on orthodontic pain do not show any sex-related differences 
in pain perception (Ngan et al., 1989; Jones and Chan, 1992; Fernandes et al., 1998; Sergl 
et al., 1998; Erdinc and Dinçer, 2004; Scott et al., 2008; Abdelrahman et al., 2015; Rahman 
et al., 2015). However, there are some studies that report greater levels of orthodontic 
pain among females (Scheurer et al., 1996; Bergius et al., 2002). In terms of general, 
experimentally induced pain, women are more likely to report pain of greater severity and 
longer duration than men. It is thought that males may under-report the level of pain they 
have experienced due to social and cultural pressures which leads them to minimise any 
outward display of distress or discomfort (Riley III et al., 1998). 
 
It is very difficult to determine whether age has any influence on the perceived severity of 
pain during orthodontic treatment, since adolescents and adults may be treated with 
different protocols. Some studies have found that younger patients experience less pain 
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than older patients (Jones, 1984; Jones and Richmond, 1985; Jones and Chan, 1992; 
Fernandes et al., 1998). However, numerous studies have also demonstrated that there is 
no relationship between age and the severity of pain experienced during orthodontic 
treatment (Ngan et al., 1989; Scott et al., 2008; Abdelrahman et al., 2015; Rahman et al., 
2015). One study has even reported that adolescents (patients between 14 and 17 years 
of age) reported the highest intensities of pain during orthodontic treatment when 
compared to pre-adolescents and adults (Brown and Moerenhout, 1991). Overall, there 
seems to be no consensus regarding the effects of age on pain perception in the 
orthodontic literature. 
 
1.5.2 Psychological variables 
The psychological well-being of patients has a significant impact on the severity of perceived 
pain (Brown and Moerenhout, 1991; Jones and Chan, 1992). Stress can play a part in the 
perception of pain. Momentary stress responses were designed as responses to aid in 
survival. However, prolonged stress, particularly of the mental variety, can have adverse 
effects on an individual by increasing sympathetic nervous activity in the absence of a 
physical threat. There is some evidence of a correlation between stress and the 
frequency/severity of perceived pain (Korszun, 2002; Okeson, 2005). Anxiety has also been 
shown to play a part in pain perception by lowering the pain threshold so that normal 
painless impulses are perceived as painful (Litt, 1996). Restorative procedures are reported 
to evoke greater levels of pain among highly anxious patients (Klages et al., 2006). 
Interestingly, simple dental procedures, such as the placement of orthodontic separators, 
have also been shown to be associated with greater pain levels among dentally anxious 
patients (Beck et al., 2014). 
 
It has been suggested that individuals with greater concerns about the severity of their 
malocclusion perceive lower intensities of pain and discomfort in the seven days following 
appliance insertion (Sergl et al., 1998). In addition, patients who demonstrated low 
motivation for orthodontic treatment experienced higher levels of orthodontic pain after 
placement of elastic separators (Bergius et al., 2008). However, conflicting evidence exists 
regarding the relationship between the perceived severity of a malocclusion and the 




Catastrophising has been shown to be associated with high-pain responders in a study 
utilising elastic separators to induce orthodontic pain. In particular, individuals with higher 
“magnification” scores (one part of the Pain Catastrophising Scale) experienced higher 
levels of pain. Magnification refers to “a person’s likelihood to exaggerate the threat value 
or seriousness of pain sensations” (Beck et al., 2014). The results from this study suggest 
that cortical pain processing may play an important role in pain perception, demonstrating 
that certain psychological characteristics can influence pain severity. Another study has 
shown that expectations of lower pain resulted in reduced levels of perceived pain, while 
expectations of higher pain resulted in amplified pain levels (Koyama et al., 2005). 
 
1.5.3 Clinical variables 
Several orthodontic studies have failed to demonstrate any significant association between 
the type of arch wire used at bond-up and the amount of pain experienced. No significant 
differences in perceived pain have been found between a superelastic and conventional 
NiTi arch wire (Fernandes et al., 1998), a NiTi and multistranded steel arch wire (Jones and 
Chan, 1992), a 0.014” and 0.016” NiTi arch wire (Erdinc and Dinçer, 2004), and 0.014” 
superelastic, thermoelastic and conventional NiTi wires (Abdelrahman et al., 2015). In 
addition, no relationship between the severity of reported pain and the amount of anterior 
or overall crowding has been found (Jones and Richmond, 1985). 
	
1.6 Measuring orthodontic pain and discomfort 
Pain is a subjective phenomenon, which is best assessed using a self-report approach. The 
VAS is the most commonly used method to measure orthodontic pain (Ngan et al., 1989; 
Jones and Chan, 1992; Scheurer et al., 1996; Bergius et al., 2000). It is a non-verbal measure, 
and consists of a line which is usually 10 cm long. Each end of the scale represents the limits 
of the pain experience. For example, the left end might be labelled “no pain”, while the 
right end is labelled “severe pain” (Duncan et al., 1989). Respondents are asked to place a 
vertical mark on the line corresponding to the level of pain they are experiencing. The 
distance of the mark from the left end of the scale is measured, and represents the severity 
of pain. The VAS is designed to offer the respondent a rating scale that has minimal 
constraints. The main advantage of this is that it provides respondents with the freedom to 
choose the exact intensity of pain that they are experiencing (Linacre, 1998). The VAS is 
easy for most patients to grasp, and children aged five and above are able to use it 
(McGrath, 1990). Some of the strengths of the VAS include its ability to discriminate 
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between small increments of pain intensity (Seymour, 1982; Langley and Sheppeard, 1983), 
its sensitivity to measuring successive responses to treatment (Melzack and Torgerson, 
1971), as well as its reproducibility (Scott and Huskisson, 1979) and reliability (Revill et al., 
1976). 
	
1.6.1 Limitations associated with measuring orthodontic pain 
The vast majority of studies which have investigated orthodontic pain have utilised paper-
based surveys to record participants’ pain at various time intervals following orthodontic 
arch wire adjustments (Jones and Chan, 1992; Scheurer et al., 1996; Erdinc and Dincer, 
2004; Fleming et al., 2009; Benson et al., 2012; Woodhouse et al., 2015). This approach 
has inherent limitations because pain surveys are often filled in retrospectively, and the 
memory of pain may be inaccurate, as memory recall is not always reliable (Bradburn et al., 
1987). Furthermore, during paper-based surveys, participants are able to look back at their 
previous  pain scores, which could influence their current and future pain ratings. Some 
studies have attempted to eliminate participants being able to look at their past pain scores 
by calling patients at the required times to ask about pain scores (Bergius et al., 2008), as 
well as asking patients to mail back their pain scores after the completion of each survey 
(Scheurer et al., 1996; Bergius et al., 2002).  
	
1.7 Genetics associated with pain 
The perception of pain is an incredibly complex process which is influenced by 
environmental and genetic factors (Mogil, 1999). In recent times, there has been increasing 
interest in the role of genetic factors that influence pain perception. To date, no studies 
have investigated whether or not there are associations between certain genetic 
polymorphisms and the intensity of pain experienced by patients undergoing orthodontic 
treatment. However, there is ample evidence that single nucleotide polymorphisms (SNPs) 
of certain genes can influence the severity of pain caused by fibromyalgia and experimental 
pain, and can even contribute to temporomandibular disorders (TMD).  
	
1.7.1 Genetics and experimental pain 
Given the lack of studies investigating the genetic basis of orthodontic pain, there is a need 
to consider other similar models in order to identify selected candidate genes. Several 
haplotypes, which refer to a set of single nucleotide polymorphisms (SNPs) on one 
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chromosome that tend to occur together, have been identified in previous studies focusing 
on experimental pain and TMD. Catechol-O-methyltransferase (COMT) is one of the most 
widely studied genes involved in human pain. COMT catalyzes the degradation of 
catecholamines such as dopamine, adrenaline and noradrenaline, and as such, is involved in 
pain processing (Belfer and Segall, 2011). The three most common COMT haplotypes are 
termed high pain sensitivity (HPS), average pain sensitivity (APS) and low pain sensitivity 
(LPS). The four SNPs of the COMT gene that contribute to these COMT haplotypes 
include rs6269, rs4633, rs4818 and rs4680. These COMT haplotypes were named 
according to their association with sensitivity to experimental pain in humans. The 
experimental pain consisted of pressure pain thresholds, thermal pain thresholds and 
tolerances, as well as ischaemic pain thresholds and tolerances. Some 11% of the variation 
in perception of experimental pain in a sample of 202 healthy females could be attributed 
to combinations of these three common haplotypes (Diatchenko et al., 2005).  
	
1.7.2 Genetics and TMD 
Numerous studies have investigated the association between genetics and TMD. The role 
of several COMT haplotypes on the incidence of TMD was recently investigated in a three-
year prospective study involving 202 women. Females who had only HPS and/or APS 
haplotypes had a 2.3-fold greater risk of developing TMD when compared to females who 
had one or two LPS haplotypes (Diatchenko et al., 2005).  
 
Interestingly, in an extension of this study, approximately a quarter of the patients with 
pain-sensitive haplotypes of the COMT gene with a history of orthodontic treatment 
developed TMD during this three-year period. However, none of the 20 patients with pain-
sensitive haplotypes who did not have a history of orthodontic treatment developed TMD 
during these three years. Thus, orthodontic treatment may increase the risk of developing 
TMD in patients with pain-sensitive haplotypes of the COMT gene – this represents a 
gene-environment interaction. In patients with pain-resistant haplotypes, orthodontic 
treatment was not associated with an increase in risk of developing TMD (Slade et al., 
2008). 
 
The Orofacial Pain Prospective Evaluation and Risk Assessment (OPPERA) project carried 
out a large case-control study in America, which included 348 patients with chronic TMD 
and 1612 controls. Some 3295 SNPs from 358 genes implicated in human pain perception 
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were tested. Nine SNPs from six different genes were associated with TMD: rs2963155, 
rs9324918 and rs33389 SNPs of the glucocorticoid receptor (NR3C1) gene, the 
rs9316233 SNP of the serotonin 2A receptor (HTR2A) gene, the rs7800170 SNP of the 
muscarinic cholinergic receptor 2 (CHRM2) gene, the rs3756612 and rs10491334 SNPs 
of the calcium/calmodulin-dependent protein kinase 4 (CAMK4) gene, the rs728273 SNP 
of the interferon-related developmental regulator 1 (IFRD1) gene, and the rs12415832 
SNP of the G protein-coupled receptor kinase 5 (GRK5) gene (Smith et al., 2011). This 
study also tested the association between COMT haplotypes and TMD. Participants with 
HPS haplotypes had an increased risk of TMD (OR = 1.28, P = 0.05). Interestingly, there 
was no significant difference between the APS and LPS haplotypes in this case-control 
study.  
 
The NR3C1 gene, located on chromosome five, codes for the glucocorticoid receptor, 
which is a binding site for cortisol. The glucocorticoid receptor is a significant component 
of the hypothalamic-pituitary-adrenal (HPA) system, the primary endocrine stress axis in 
humans. This system has been previously been implicated in the development of TMD 
(Korszun et al., 2002). The OPPERA project found that the rs2963155 SNP, located in the 
long intron of the NR3C1 gene, was associated with TMD (OR = 0.62, P = 6.15 x 10-5). 
The minor allele is G, and the minor allele frequency (MAF) is about 20-24% in both 
Caucasians and African-Americans. The minor G allele had a protective effect against TMD 
(Smith et al., 2011).  
 
The HTR2A gene, located on chromosome 13, codes for a serotonin receptor. The 
serotonergic system is known to influence both nociceptive and affective pathways. The 
OPPERA project found that the rs9316233 SNP, an intronic polymorphism, was also 
associated with TMD (OR = 0.64, P = 3.44 x 10-4). The minor allele is G, and the MAF is 
about 30%. Interestingly, the minor G allele was protective against TMD in females, but not 
in males. For white females, the OR was 0.39, P = 2.3 x 10-4 (Smith et al., 2011). An earlier 
study found that rs6313, a synonymous polymorphism located on exon one of the HTR2A 
gene, was associated with TMD (Mutlu et al., 2002).  
 
A smaller case-control study conducted in Italy recruited 50 patients affected by TMD and 
132 controls. The entire COMT gene was sequenced for all of these participants. Some 40 
COMT variants were found, 18 of which were novel discoveries. The SNPs rs1655656, 
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rs165722 and rs4646310 were found significantly more frequently in TMD patients when 
compared to the controls. All of these SNPs are located in the promoter region of the 
COMT gene. The SNPs rs1655656 and rs4646310 were novel discoveries - patients with 
the CC genotype of rs1655656 were 5.3 times more likely to suffer from TMD when 
compared to the patients with the GG genotype, while patients with the AG genotype of 
rs4646310 were 2.6 times more likely to suffer from TMD when compared to patients 
with the GG genotype (Michelotti et al., 2014). It has been proposed that the SNPs located 
in the promoter region of the COMT gene could alter DNA transcription, RNA splicing, 
mRNA stability, or mRNA transport and translation, ultimately leading to an increased risk 
of TMD (Nackley et al., 2006). Intriguingly, this study did not report on the effect of the 
three most common COMT haplotypes, as mentioned previously, on the risk of TMD.   
	
1.8 Catechol-O-methyltransferase (COMT)  
Catechol-O-methyltransferase (COMT) is one of the most widely studied genes involved 
in human pain (Belfer and Segall, 2011). COMT is an enzyme that transfers a methyl group 
from S-adenosyl methionine to a catechol substrate. This results in the production of S-
adenosyl-L-homocysteine, as well as an O-methylated catechol (Axelrod and Tomchick, 
1958; Guldberg and Marsden, 1975). COMT catalyzes the degradation of catecholamines 
such as dopamine, adrenaline and noradrenaline. These neurotransmitters are involved in 
a vast array of physiological processes such as cognition, cardiovascular function, stress 
response, and pain processing (Belfer and Segall, 2011). COMT is involved in the regulation 
of extracellular catecholamine concentrations, especially in the prefrontal brain region and 
peripheral tissues. The concentration of catecholamines can affect the pain tract at multiple 
levels (Tammimaki and Manniesto, 2012).  
 
The COMT gene codes for two COMT protein isoforms – soluble COMT (S-COMT) and 
membrane-bound COMT (MB-COMT) (Salminen et al., 1990; Lundstrom, 1991). The 
COMT gene is located on the long arm of chromosome 22, at the gene map locus of 
22q11.2. It spans about 27kb, and contains two promoters. These two promoters direct 
the synthesis of two distinct transcripts: 
1) The most distal 5’ promoter (P2) regulates the synthesis of a 1.5kb transcript, which 
encodes both MB-COMT (271 amino acids) and S-COMT (221 amino acids) 
(Tenhunen et al., 1993; Tenhunen et al., 1994). 
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2) The second promoter (P1) is located between two separate ATG (translation 
initiation) codons in exon 3. P1 regulates the synthesis of a 1.3kb transcript, which 
encodes only S-COMT (Tenhunen and Ulmanen, 1993; Tenhunen et al., 1994). 
 
Translation of MB-COMT and S-COMT are initiated from two separate ATG translation 
initiation codons in exon 3 (Berrocci et al., 1991; Lundstrom et al., 1991). The sequence 
downstream of the S-COMT start codon is identical in both P1 and P2. The COMT gene 
contains a single translation stop codon, located in exon 6. A diagram of the structure of 
the COMT gene is displayed below in Figure 1.1.  
 
Numerous splice variants of the 1.5kb COMT transcript have been found in the human 
brain (Tunbridge et al., 2007). Currently, the functional significance of these splice variants 











In the brain, the ratio of MB-COMT to S-COMT enzyme is about 70:30. However, in 
peripheral tissues, the S-COMT form of the enzyme is predominant (Tenhunen et al., 1994; 
Chen et al., 2004). There are high levels of the 1.5kb COMT transcript (which encodes 
both the MB-COMT and S-COMT enzymes) and very low levels of S-COMT transcripts 
within the brain, demonstrating the importance of the 1.5kb transcripts for translation of 
both the COMT isoforms. The MB-COMT enzyme has a much higher affinity 
Figure 1.1 Source: Andersen and Skorpen, 2009. Structure of the human COMT gene, but not to scale. The line represents 
introns, while the boxes represent exons. The approximate sizes of introns and exons are indicated. Filled boxes correspond to 
protein coding regions. White boxes are untranslated regions. Translation start codons for MB-COMT (MB-ATG) and S-COMT 
(S-ATG) are indicated, as are the two promoters, P1 and P2. The TGA stop codon is located in exon 6 (Tenhunen et al., 1994; 
Weinshilboum, 2006).  
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(approximately ten-fold) for dopamine and adrenaline when compared with the S-COMT 
enzyme (Lotta et al., 1995). Therefore, MB-COMT is better suited to metabolise the 
concentrations of catecholamines found in the brain (Roth, 1992). COMT has been 
detected in a number of cell types located within the brain: these include non-neuronal, 
glial and neuronal cells (Kaplan et al., 1979; Karhunen et al., 1994; Kastner et al., 1994). The 
prefrontal cortex and striatum neurons seem to be the main cell populations in the brain 
that express COMT (Matsumoto et al., 2003). In vitro studies utilising cultured cells with 
overexpression of COMT have demonstrated that MB-COMT is associated with 
intracellular membranes, for example, the rough endoplasmic reticulum. S-COMT is 
located in the nucleus and cytoplasm (Ulmanen et al., 1997). However, it is not known 
whether this in vitro situation is representative of what actually occurs in vivo.  
	
1.8.1 COMT activity and pain in animal studies 
Numerous studies have investigated the effects of altering COMT activity on pain, using 
genetically modified mice. These studies have used COMT knockout mice, as well as 
transgenic mice that overexpress the Val158 (high COMT activity) variant of the human 
COMT gene in the prefrontal cortex. The homozygous COMT knockout mice (with no 
COMT activity) had increased pain sensitivity, while the transgenic mice with 
overexpression of the Val158 variant had reduced sensitivity to painful stimuli (Papaleo et 
al., 2008). In addition, when COMT inhibitors were administered to mice and rats, there 
was an increase in experimental pain sensitivity (Diatchenko et al., 2005; Nackley et al., 
2007; Kambur et al., 2010). 
	
1.8.2 Regulation of catecholamine concentrations in the brain (derived from animal studies) 
There are regions within the brain that contain a high dopamine transporter density, for 
example, the striatum. In these high dopamine transporter regions, the primary method of 
terminating the dopamine signal is by uptake of dopamine into the dopamine nerve 
terminals via dopamine transporters. Therefore, COMT plays a minor role in terminating 
dopamine signals in these regions (Cass et al., 1993; Giros et al., 1996; Moron et al., 2002; 
Eisenhofer et al., 2004). However, there are areas in the brain with a low dopamine 
transporter density, for example, in the prefrontal cortex (Sesack et al., 1998). In these 
regions, the dopamine signal is terminated by dopamine uptake into postsynaptic neurons 
or non-neuronal cells (Wilson et al., 1988; Trendelenburg, 1990; Manniesto et al, 1992). 
After uptake into these cells, the dopamine is metabolised by COMT (Matsumoto et al., 
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2003). Thus, areas which rely on COMT for termination of dopamine signals, such as the 
prefrontal cortex, are affected by variations in COMT activity (Cass et al., 1993; Giros et 
al., 1996; Moron et al., 2002; Eisenhofer et al., 2004; Yavich et al., 2007; Kaenmaki et al., 
2010). It therefore stands to reason that COMT is likely to play a key role in the modulation 
of dopamine neurotransmission in the prefrontal cortex. 
 
1.8.3 COMT genetic variation 
The COMT gene locus contains numerous single nucleotide polymorphisms with minor 
allele frequency greater than 1%1. Most of these SNPs are located in noncoding regions, or 
if they are located in coding regions, do not alter the amino acid sequence of the COMT 
protein. It must be noted that SNPs in noncoding regions, or silent SNPs, can have 
significant effects on processes such as DNA transcription, RNA splicing, mRNA stability, 
as well as mRNA transport and translation (Andersen and Skorpen, 2009).  
 
Genetic variation in the COMT gene has been associated with several different pain 
conditions. These include differences in pain perception caused by experimental pain stimuli 
(Diatchenko et al., 2005) and variable susceptibility to common pain conditions such as 
fibromyalgia (Gursoy et al., 2003; Vargas-Alarcon et al., 2007; Tammimaki and Manniesto, 
2012), migraine (Emin Erdal et al., 2001) and TMD (Diatchenko et al., 2005) to name a 
few. A more comprehensive table of COMT SNPs and their associated pain conditions is 
listed in Table 1.1.  
 
The most studied SNP in the COMT gene is rs4680. This polymorphism results in a 
substitution from valine (Val) to a methionine (Met) at codon 158 for MB-COMT, and 
codon 108 for S-COMT. The consequence of this amino acid substitution is an enzyme 
with a lower thermostability, ultimately resulting in a dramatic three to four-fold decrease 
in the activity of the COMT enzyme (Lotta et al., 1995). The Val158Met polymorphism 
therefore governs the level of the COMT activity (Lotta et al., 1995; Chen et al., 2004), 
and has been associated with sustained muscular pain (Zubieta et al. 2003), experimental 
pain (Diatchenko et al., 2006), headache (Hagen et al., 2006), migraine (Emin Erdal et al., 





Table 1.1 Single nucleotide polymorphisms of the COMT gene which have been linked to pain conditions 
SNP Study Number of 
participants 
Type of pain Conclusion 
rs4680  Zubieta et al. 2003 29 Sustained muscular pain Met allele is associated with pain ratings as well as reduced activation of µ-opioid system 
 Diatchenko et al., 2006 202 Experimental pain rs4680 associated with temporal summation of heat pain left 
 Hagen et al., 2006 2451 Headache Val/Val genotype had lower prevalence of non-migrainous headache 
 Emin Erdal et al., 2001 126a  Migraine Met allele (homozygous and heterozygous) associated with migraine 
 Vargas-Alarcon et al., 2007 248a Fibromyalgia rs4680 associated with fibromyalgia in Spaniards, but not Mexicans 
 Gursoy et al., 2003 122a Fibromyalgia Val/Met and Val/Val genotypes associated with fibromyalgia 
rs6269 Diatchenko et al., 2005 202 Experimental pain (thermal, 
pressure, ischaemic pain) 
rs6269 associated with experimental pain 
 Kim et al., 2006 735 Heat and cold pain rs6269 weakly associated with cold pain sensitivity 
 Vargas-Alarcon et al., 2007 248a Fibromyalgia rs6269 associated with fibromyalgia in Spaniards, but not Mexicans 
rs4818 Diatchenko et al., 2005 202 Experimental pain (thermal, 
pressure, ischaemic pain) 
rs4818 associated with experimental pain 
 Vargas-Alarcon et al., 2007 248a Fibromyalgia rs4818 associated with fibromyalgia in Spaniards, but not Mexicans 
rs4633 and rs4818 George et al., 2008 58 Shoulder pain High pain catastrophising and COMT APS/HPS diplotype associated with increased pre and 
post-op persistent pain 




a case control study 




A recent study has investigated the complex pattern of variation and linkage disequilibrium 
(nonrandom allelic association) across the COMT gene in 45 human populations using 28 
SNPs. Common haplotypes (sets of associated SNP alleles) from diverse evolutionary 
lineages potentially harbour undetected variants with functional consequences (Mukherjee 
et al., 2010). Linkage disequilibrium analysis has revealed that in the case of most human 
populations, COMT contains three haploblocks2. In most instances, three to four common 
haplotypes cover the entire genetic diversity across each haploblock (Gabriel et al., 2002).  
 
As described previously, Diatchenko and colleagues have described three common 
haplotypes which account for 96% of all haplotypes observed (Diatchenko et al., 2005). 
These haplotypes consist of four SNPs – rs6269, rs4633, rs4818 and rs4680. The three 
haplotypes were named low pain sensitivity (LPS), average pain sensitivity (APS) and high 
pain sensitivity (HPS), with up to a 20-fold difference in COMT activity between the LPS 
and HPS haplotypes. The APS haplotype containing the Met158 allele correlated with 
intermediate activity of the COMT enzyme. The Val158 allele correlated with either high 
or low COMT enzyme activity, depending on the three other SNP alleles that contribute 
to the haplotype. This occurs via alteration of the mRNA secondary structure, which either 
permits or restricts the translation of COMT (Nackley et al., 2006).  
 
The secondary structure is the two-dimensional pairing of nucleotides within an RNA 
sequence, which results in characteristic folds, stems and loops, which ultimately determine 
the rate of mRNA translation into protein. Despite both the HPS and LPS haplotypes 
containing the Val158 allele (high COMT activity), the HPS haplotype (low COMT activity) 
has restricted translation of COMT, which is believed to be because of its long, rigid stem 
loops that inhibit protein synthesis. The resultant COMT has also shown to metabolise 
11.4 times less catecholamine compared with that of the LPS haplotype in a cell culture 
assay (Nackley and Diatchenko, 2010). Therefore, individuals who are homozygous for the 
LPS haplotype will metabolise catecholamines more efficiently, and as a result, will have 
reduced catecholamine-mediated neurotransmission (Voelker et al., 2009). This is 
illustrated in Figure 1.2. Catecholamines are essential components of both the ascending 
and descending pain tracts, and any changes in catecholamine levels may increase or 





























Because no previous orthodontic research has investigated the role of genetics on pain 
associated with fixed appliances, we used this literature review to select six candidate SNPs 
and haplotypes from three different genes. More information about these chosen candidate 















Figure 1.2 Source: Belfer and Segall, 2011. A warrior-worrier model of the relationship between COMT metabolism and 
COMT “pain sensitivity” alleles in different species: COMT enzyme is depicted as “pacman” and catecholamines dopamine, 
adrenaline and noradrenaline as small black dots. High COMT metabolism associated with human or mouse alleles or certain 
rat strains, likely results in less catecholamine signaling in the adrenergic receptor.  
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Table 1.2 The SNPs and haplotypes of the three candidate genes investigated in this research
Candidate gene SNP Minor allele Minor 
allele 
frequency 
Type of pain  Study 
COMT rs6269 G 
 
0.3568 Experimental pain 
 
Diatchenko et al., 2005 
    Heat and cold pain Kim et al., 2006 
    Fibromyalgia Vargas-Alarcon et al., 2007 
 
 rs4680 A 0.3692 Sustained muscular 
 
Zubieta et al. 2003 
    Experimental pain 
 
Diatchenko et al., 2006 
    Headache Hagen et al., 2006 
 
    Migraine  Emin Erdal et al., 2001 
 
    Fibromyalgia Vargas-Alarcon et al., 2007; Gursoy et al., 2003 
 




  Experimental pain 
 
Diatchenko et al., 2005 
    TMD Diatchenko et al., 2005 
 
NR3C1 rs2963155 G 0.2228 TMD Smith et al., 2011 
 
HTR2A rs9316233 G 0.2977 TMD Smith et al., 2011 
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1.9 Aims and objectives 
To investigate the relationship between demographic, clinical, genetic factors, and the 
severity of pain experienced by patients during orthodontic fixed appliance treatment.  
 
The specific objectives of the study were:  
1. To develop an Android smartphone application to measure pain in real-time at the 
teeth after an orthodontic adjustment.  
2. To describe the pain profile of participants after the fixed appliances are adjusted, 
and investigate whether gender, age, time in treatment, or details of the orthodontic 
adjustment are predictors of the pain experienced.   
3. To investigate whether certain genotypes/haplotypes of the COMT, HTR2A and 
NR3C1 genes (which are associated with TMD) are associated with the pain 
experienced during orthodontic treatment with fixed appliances.  
	
1.10 Hypotheses 
1) The severity of pain during orthodontic fixed appliance treatment is influenced by 
gender, age, time in treatment with fixed appliances, and the details of the 
orthodontic adjustment visit.  
2) The severity of pain during orthodontic fixed appliance treatment is associated with 











2.1 Research approach 
A prospective longitudinal study design was employed using the STROBE guidelines (von 
Elm et al., 2007). Some of the patients recruited in this research had already been enrolled 
in an ongoing genetics study within the Sir John Walsh Research Institute, University of 
Otago.   
	
2.2 Study sample 
A convenience sample of 82 patients (mean age = 15.2 years; 56.1% female) undergoing 
treatment at the orthodontic clinic, Faculty of Dentistry (University of Otago), participated 
in this study. Patients were invited to participate in the study by approaching them in the 
clinic, as well as contacting them by telephone.  
	
2.2.1 Inclusion criteria 
Participants were included if they were:  
1) Currently undergoing, or about to commence, orthodontic treatment with fixed 
appliances in at least one arch 
2) Younger than 18 years of age 
3) Willing to participate and provide informed consent 
	
2.2.2 Exclusion criteria 
Participants were excluded if they had:  
1) Craniofacial syndromes such as cleft lip and/or palate 
2) Undergoing orthognathic surgery 
3) A diagnosed depressive disorder 
4) Any chronic pain syndrome 
5) Used any neurologically-acting medication or medication that could potentially 
affect pain sensitivity (such as antidepressants) 
6) Active caries or periodontal disease 
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Participants were provided with an explanation of the research goals and procedures, and 
the investigator was available to all participants during the project, should any stress, harm, 
or related concerns have arisen.  
	
2.2.3 Sample size 
With a minor allele frequency of the COMT gene estimated at 0.35, and type I error set 
at 5%, it was estimated that a cohort of more than 300 participants would allow 80% 
power to detect a relative risk of 1.5 or greater. However, since this project was a pilot 
study, our goal was to recruit as many participants as we could in the available timeframe. 
It is expected that further patient recruitment will continue over the next few years until 
the target sample size is reached.   
	
2.3 Development of smartphone app 
To date, all orthodontic pain studies have used paper-based visual analogue scales (VAS). 
Therefore, it is impossible to determine whether participants had completed the VAS 
scores at the correct time, or if the VAS scores were completed retrospectively. This leads 
to potential concerns regarding the validity and reliability of the data. Additionally, paper-
based versions of the VAS allow participants to look back at their past pain scores, which 
could potentially influence the next set of pain scores that they are required to complete. 
In order to overcome these limitations, a smartphone app was developed to measure pain.  
 
WSH, MF, JA and MA were involved in designing and developing the app. MA was 
employed to code and produce the app. The app was designed to be simple and easy to 
use for the young patients who would be participating in this research project. In order to 
maximise the likelihood of participants completing all of the pain questionnaires, the app 
was designed to send audio alerts to the participants at the times the pain questionnaires 
needed to be filled in. The app only allowed participants to complete the pain 
questionnaires up to three hours before, and up to three hours after the scheduled times. 
Participants were not able to enter pain scores outside this window. If the participants did 
not enter their pain scores within this window, a missing score was recorded for that 
session. The app allowed us to determine whether or not participants filled in the pain 
questionnaires at each time point, and also recorded exactly what time the participants 
filled in the pain questionnaires. This method guaranteed the accuracy of the collected data, 
because we were able to verify that the pain questionnaires were filled in at the correct 
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time. By using an app, participants were also unable to refer back to their previous pain 
scores, which could have potentially influenced their current pain scores (leading to bias). 
	
2.3.1 Technical details of app development 
The Android pain app was developed using the Eclipse integrated development 
environment software (Luna version 4.4.21) with the Android Eclipse Plugin, to target 
devices running Android versions 3.0 to 6.0.  
 
The app would present the participant with an Android system notification (including a 
vibration and audio cue, and a text display) at the scheduled questionnaire session time. 
Clicking the notification would launch the app, or else the app could be launched from its 
icon on the smartphone’s application list. 
 
Users would iterate through each page of questions, entering their answers via radio 
buttons for mutually exclusive answers, check buttons for mutually inclusive answers, sliders 
to answer on a continuum (VAS scores), and text and numerical entry boxes using the 
default Android onscreen keyboard and number pad.  
 
Questionnaire answers were stored on a local database (SQLite2) at the completion of 
each session. Once all the sessions were complete, the data was retrieved from the 
database, compiled into a single comma-separated-values file, and emailed automatically 
from within the pain app, using the JavaMail API3 to a Google Mail account under control 
of the questionnaire administrator, from where it could be downloaded and analysed. If 
the app detected no internet connection when attempting to send the email, the user 
would be alerted and prompted to connect to the internet from within the app. This would 
continue until internet connection was made, upon which time the app would send the 
email. 
	
2.3.2 Testing phase 
WSH was involved in testing the app on 10 smartphones before the participants started 






accuracy of the exported data when compared to the input data. Under ideal testing 
conditions, the app was deemed to be ready for use in the study.  
	
2.3.3 Some of the app-related problems encountered during the study 
The app was more problematic while collecting data in the actual study.  Data was lost if 
the app was shut down unexpectedly, if the phone was turned off, or if the phone ran out 
of battery. As a result of the lost data, approximately 12 patients were required to repeat 
the pain questionnaires on the pain app.  
 
In addition, some participants missed a number of pain questionnaires, despite the app 
sending out alerts at every time point that pain scores were required. In order to obtain 
fairly complete data, participants were asked to completely repeat the three-day pain 
survey at a subsequent adjustment appointment of their fixed appliances, if three or more 
(out of the seven) pain entries were missing. Unfortunately, the exact number of the 
participants who had to repeat the pain questionnaires was not recorded. However, it was 
less than 15% of the sample.    
	
2.4 Experimental procedure 
This study consisted of two phases. Phase one involved collection of demographic data and 
DNA from participants, while phase two involved the use of a mobile phone app to assess 
the pain in the three days after the participants’ fixed appliances were adjusted. 
	
2.4.1 Phase one 
Participants completed a self-report questionnaire which provided information regarding 
sociodemographic details (such as age, gender and ethnicity). Participants also completed 
a psychological questionnaire which included the Pain Catastrophising Scale for Children, 
the Corah Dental Anxiety Scale, and the State-Trait Anxiety Inventory for Children (see 
Appendix 7.1). However, the information collected from these psychological 
questionnaires was not utilised in this thesis.  
 
Study participants were asked to provide a blood sample in the first instance. If participants 
declined to give blood, they could provide a saliva sample instead. A blood sample was 
preferred over a saliva sample, as blood contains a greater quantity and quality of DNA 
when compared to that of saliva.  A registered nurse collected blood samples on-site using 
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standard venepuncture procedures. The samples included a 10 mL EDTA tube that was 
used for DNA preparation, and a 5 mL gold top SST tube for serum. The SST vacutainers 
were centrifuged at 3,500 rpm on-site, and then taken to the Merriman Laboratory 
(University of Otago) for storage. When venepuncture was refused, 10 mL of saliva was 
collected instead, using specific saliva kits (DNA genotekTM Oragene-500 kits).  
 
The DNA was extracted using a chloroform extraction with an ethanol precipitation 
method on whole blood (buccal cells for the saliva samples). Five SNPs from the candidate 
genes COMT (rs4680, rs6269, rs4646310), HTR2A (rs9316233) and NR3C1 (rs2963155) 
were genotyped for all of the participants. Genotyping was conducted using TaqMan SNP 
genotyping assays (purchased from Thermo Fisher; 5 Caribbean Dv, Scoresby, VIC 3179, 
Australia) in conjunction with KAPA Probe Fast Master mix on a Lightcycler 480 real-time 
PCA machine. Genotyping was replicated in 10% of the population as a quality control. 
Haplotypes were phased using PLINK1.9.  
	
2.4.2 Phase two 
Immediately after participants had their fixed appliances adjusted, they were issued with an 
Android smartphone (Vodafone Smart Prime 6 with a 5” colour display). They then logged 
onto a specially designed pain application and completed the baseline pain questionnaires 
under the supervision of the primary investigator (WSH). Participants were able to ask 
WSH for help if they did not understand any of the questions asked by the pain application. 
Participants were also given an information sheet with details about the app and pain 
questionnaires (see Appendix 7.2). 
 
VAS’s were used to quantify the amount of pain experienced (Figure 2.1). For this study, 
an adapted version of the traditional paper-based VAS was used, in the form of a digital 
VAS. Instead of using a pen to place a mark on the line, participants used their finger to 
drag a small dot to represent their pain level. On the standardised smartphones that we 















The application asked participants to rate pain at (1) baseline; (2) 8pm on the first evening; 
(3) 8am on the second morning; (4) 8pm on the second evening; (5) 8am on the third 
morning; (6) 8pm on the third evening; and (7) 8am on the fourth morning. Overall, there 
were a total of seven pain questionnaires over approximately 72 hours after the 
participants’ fixed appliances were adjusted. An audio alert rang out at each of the seven 
time points to alert participants to complete the questionnaire. Participants were able to 
enter pain scores up to three hours before, and three hours after each scheduled time. 
Participants were not able to enter pain scores outside these times.  
 
At each pain questionnaire, participants were asked about consumption of pain relief, 
resting pain at their teeth, pain at their teeth immediately after chewing a piece of gum 
twenty times (Wrigley Extra, peppermint or spearmint flavour), orofacial pain, and 
headaches (refer to Appendix 7.3 for the exact flow of the app). Participants were asked 
not to chew gum unless the app asked them to, in the three days that they were 
undertaking the pain questionnaires. In addition, participants were not given specific 
instructions on whether to chew the gum with their front teeth or back teeth.  
 
It is important to note that the type of orthodontic activation (i.e. details of what was 
performed at the adjustment visit) and time in treatment was not standardised for 
participants. For example, it was not possible to have all of our patients record their pain 
immediately after bond-up with fixed appliances. However, details regarding the amount 






































Figure 2.2 A patient using the Android pain application 
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2.5 Data storage 
2.5.1 Storage of questionnaires 
Hard-copy baseline questionnaires filled out by all participants were kept in secure storage 
within the Faculty of Dentistry, University of Otago. These questionnaires will be retained 
for up to 10 years at the above location. Only the investigators involved in this study were 
able to access these questionnaires.  
	
2.5.2 Storage of DNA samples 
All DNA samples obtained during the study were securely stored in such a way that only 
the investigators of the study were able to gain access to them. These DNA samples will 
be retained for up to 10 years in the Merriman Laboratory at the Biochemistry Department 
at the University of Otago. No other external source, commercial or non-commercial, will 
have access to any of this information without the permission of the study 
participants/parents. 
 
2.5.3 Storage of pain application data 
The data from the pain application was automatically emailed to a secure Gmail account. 
Only the investigators were able to access this account.  
	
2.6 Ethical approval 
This study was approved by the University of Otago Human Ethics Committee in February 
2016 (reference H15/124). Written and informed consent forms were collected from all 
study participants. In addition, parental consent was obtained for study participants under 
the age of 17 years. Appendix 7.4 contains a copy of the ethics approval. Appendix 7.5 
contains a copy of the information sheets for parents and participants, and the 
participant/parental consent forms. 
	
2.7 Maori consultation 
Consultation with the Ngai Tahu Research Consultation Committee was completed in 
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3. Ecological momentary assessment of orthodontic pain profiles 
in children and adolescents undergoing orthodontic treatment1 
	
3.1 Introduction 
Many patients report pain as being the worst aspect of orthodontic treatment (Oliver and 
Knapman, 1985). Pain is incredibly common, with more than 90% of patients experiencing 
pain and discomfort at some point during their orthodontic treatment (Scheurer et al., 
1996; Erdinc and Dinçer, 2004). Surprisingly, it has been reported that the pain following 
placement of an initial arch wire is usually more severe, and lasts for longer than the pain 
following orthodontic premolar extractions (Jones and Chan, 1992).  
 
A multitude of studies have investigated the onset of pain following the application of fixed 
appliances. It is generally accepted that pain begins a few hours after an orthodontic force 
is applied, peaks around 24 hours, lasts for between three to five days, and returns to 
baseline levels after about seven days (Ngan et al., 1989; Jones and Chan, 1992). A mean 
value of approximately 50 mm on a 100 mm visual analogue scale was reported 24 hours 
after bond-up with full upper and lower fixed appliances (Woodhouse et al., 2015). 
Therefore, pain at the beginning of orthodontic treatment with fixed appliances can be 
regarded as significant and of moderate intensity for the average patient. However, it must 
be noted that pain levels experienced during orthodontic treatment can vary drastically 
between different individuals (Krishnan, 2007).  
 
Most studies investigating orthodontic pain have used paper-based surveys to record 
participants’ pain at various time intervals following orthodontic adjustments (Jones and 
Chan, 1992; Scheurer et al., 1996; Erdinc and Dincer, 2004; Fleming et al., 2009; Benson et 
al., 2012; Woodhouse et al., 2015). This approach has inherent limitations because pain 
surveys are often filled in retrospectively, and the memory of pain may be inaccurate, as 
memory recall is not always reliable (Bradburn et al., 1987). Furthermore, during paper-
based surveys, participants are able to look back at their previous  pain scores which could 
influence their current and future pain ratings. Some studies have attempted to resolve this 
problem by calling patients at the required times to ask about their current pain scores 
																																																						
1 Chapter has been submitted to Seminars in Orthodontics for publication in a special issue. 
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(Bergius et al., 2008), as well as asking patients to mail back their pain scores at each time 
point (Scheurer et al., 1996; Bergius et al., 2002).  
 
Ecological Momentary Assessment (EMA) allows participants to report repeatedly on 
various experiences “in real-time, in real-world settings, over time and across contexts”. 
EMA enables researchers to minimise subjects’ recall bias and maximise ecological validity 
since the data is collected in the subjects’ natural environment. EMA studies are often used 
to assess particular events in subjects’ lives, or to assess subjects at periodic intervals. 
Various technological devices such as written diaries, telephones, electronic diaries and 
physiological sensors can be used in EMA (Shiffman et al., 2008). 
 
The aim of this study was to design a smartphone app that could regularly measure pain 
levels of participants following the adjustment of their fixed appliances. This app would 
provide ratings of current pain, information about the time that participants filled in their 
surveys, as well as information on when participants missed their pain surveys. We have 
used this app to investigate pain profiles in a sample of patients undergoing fixed 
orthodontic treatment. Specifically, we aim to determine the association between pain and 
several demographic and treatment factors such as gender, age, time in treatment, and type 


















The study utilised a longitudinal prospective design, which was developed according to the 
STROBE guidelines (von Elm et al., 2007). The study was set between June 2016 and April 
2017 and was based in the orthodontic clinic at the Faculty of Dentistry, University of 
Otago, New Zealand. 
 
A convenience sample of 82 orthodontic patients who fulfilled the inclusion and exclusion 
criteria were recruited (see Chapter 2 for more details about the recruitment process). 
Eligible participants filled in a questionnaire that asked about basic demographic 
information. Following this questionnaire, participants were shown how to use an Android 
smartphone application that was developed as part of this study to record the severity of 
pain at the teeth following an adjustment of the fixed appliances. 
 
Immediately following an orthodontic adjustment appointment, regardless of the stage of 
treatment that they were in, the participants were issued with an Android smartphone 
(Vodafone Smart Prime 6, with a 5” colour display). Participants then filled out the first pain 
survey on the pain app, under the supervision of the primary investigator (WSH). 
Participants were required to fill out pain surveys at (1) baseline (immediately after an 
orthodontic adjustment); (2) 8pm on day one; (3) 8am on day two; (4) 8pm on day two; 
(5) 8am on day three; (6) 8pm on day three; and (7) 8am on day four. Each pain survey 
asked about analgesic consumption, resting pain at the teeth, and pain at the teeth 
immediately after chewing a piece of chewing gum twenty times (Wrigley Extra, 
peppermint or spearmint flavour, Wrigley, Chicago, Illinois, USA). A digital sliding VAS was 
used to record the severity of pain experienced -  the left side of the VAS was labelled “no 
pain at all”, while the right side was labelled “worst pain imaginable”. The digital VAS was 
9.35 cm long, which differs slightly from the 10 cm long VAS diagrams used in traditional 
paper-based forms. Participants dragged a small circular slider (measuring 1.5 mm in 
diameter) to rate the severity of pain felt at their teeth. They were asked not to chew gum 









The primary outcome measurements were pain at the teeth at rest and after chewing gum, 
in the 72 hours after an orthodontic adjustment. Pain scores were assessed timewise and 
across the whole three-day observation period as area under the curve (AUC) of perceived 
level of pain. Secondary outcomes included reported use of oral analgesics, headache, and 
facial pain. 
	
3.2.2 Statistical analysis 
Statistical analyses were carried out using SPSS Software (version 23, IBM, NY, USA).  
Preliminary analyses entailed normality tests and tests for equality of variances – assumption 
of normal distribution was tested using a one sample Kolmogorov-Smirnov test.  
 
A repeated measurement Friedman analysis of variance was used to test the effects of time 
(seven time points over 72 hours) on the two VAS variables (“current pain at teeth” and 
“pain at teeth after chewing”). The square root of the area under the curve (AUC, normally 
distributed) was calculated for VAS scores of current pain at teeth and pain at teeth after 
chewing, and entered as dependent variables in a general linear model, with age, gender, 
details of orthodontic adjustment, and time in treatment as covariates.  Type I error was 




















The mean age of participants was 15.2 years (SD = 1.6 years) and ranged between 10.8 
and 18.2 years. There were a greater number of female participants compared to male 
participants (F = 56.1%). Seventy-one (86.6%) participants identified themselves as being 
NZ European only, while seventy-six (92.7%) participants identified as being NZ European 
and Maori/Pacific Islanders. Two participants (2.4%) identified as being Maori or Pacific 
Island only, while four participants (4.8%) were of “other” ethnicity (Niuean, Chinese, 
Bangladeshi and Colombian). The mean time in orthodontic treatment was 12 months (SD 
= 8.4 months), with a range of 0 to 32 months.  The vast majority of participants (95.1%) 
had fixed appliances in two arches, while 4.9% had fixed appliances in one arch only.  
	
3.3.2 Details of orthodontic adjustments 
The distribution of the study sample by the type of orthodontic adjustments are presented 
in Table 3.1.  
	
Table 3.1 Type of orthodontic adjustment across the study sample. 
 




No arch wire changes +/- minor bends in arch wire 5 6.1 
Power chain replacement +/- minor bends in arch wire 27 32.9 
One arch wire changed 27 32.9 
Two arch wires changed 14 17.1 
New bond up in at least one arch 9 11 
 
 
The majority of participants had one arch wire change, or power chain replaced with or 
without minor bends in the arch wires. A small number of participants had no arch wire 
changes with or without bends in the arch wires.  
 
3.3.3 Missing data 
Overall, 6.4% of pain surveys were not completed by the participants. Missing data was 
handled by substituting the missing pain score with that from the previous pain survey, 




3.3.4 Timeliness of pain scores 
Some 93.6% of the pain surveys were filled in by the participants. On average, participants 
filled in the pain surveys 21 minutes later than expected (ranging from 167 minutes early 
to 177 minutes late, SD = 56 minutes).  
 
3.3.5 Pain relief 
Only 37.8% of the participants reported using analgesics (paracetamol and/or ibuprofen) 
at some point in the three days following adjustment of their fixed appliances.  
	
3.3.6 Headache 
Nearly one-quarter of the participants reported headaches (left or right temple areas) at 
least once during the three-day study period. 
	
3.3.7 Pain and time 
Pain levels (by VAS) varied significantly over the 72-hour assessment period for both 
current pain at teeth (F=19.4; P<0.001), and pain at the teeth after gum chewing (F=22.9; 
p<0.001; Figure 3.1).  
 
Participants reported mild levels of current pain at the teeth immediately after the 
orthodontic baseline appointment, with a mean VAS score of 10.6 % (standard error = 1.6 
%).  Compared to baseline, the pain scores rose steadily in the first day, and peaked on the 
morning of the second day (approximately 19 hours after the fixed appliances were 
adjusted) where the mean VAS score increased to 26.5 % (standard error = 2.6%; 
p=0.004). The pain scores then reduced steadily between 19 and 72 hours after the 
orthodontic adjustment. On the evening of day three and the morning of day four, the 
mean VAS scores did not differ significantly from the baseline scores (p>0.05; Figure 3.1).   
 
Mild levels of pain at the teeth after gum chewing were also reported immediately after 
the orthodontic baseline appointment, with a mean VAS score of 12.7% (standard error = 
2.0%). VAS pain on chewing increased rapidly, with a mean VAS score of 33.7% by 8pm 
on the first evening (p<0.001). The pain levels after chewing peaked on the morning 
following the orthodontic adjustment (approximately 19 hours after), with a VAS score of 
36.8% (standard error = 3.4%; p<0.001). By 8pm on day two, the gum chewing VAS scores 
had only decreased slightly, with a mean VAS score of 31.9 (p=0.003). Pain on chewing 
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decreased steadily after this. At 8am on day four, the pain on chewing did not differ from 
the baseline pain on chewing score (p>0.05; Figure 3.1). Chewing gum triggered greater 
amounts of pain compared to the resting pain at the teeth, across all the time points. 
 
 
	 	 	 	 	 	 	 	 	 	 	














































Figure 3.1 Time profile of current pain at teeth and pain at teeth after chewing gum over the three-day study period (error bars 
represent the 95% confidence interval). 
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Cumulative pain levels (i.e. total pain) experienced at the teeth over the three days of 
testing were assessed using the area under the curve (AUC) of VAS scores for both current 
pain at the teeth and pain at the teeth after gum chewing. The AUC of current pain and 
pain on chewing was not significantly influenced by age (F £ 1.9; p ³ 0.172), gender (F £ 
0.6; p ³ 0.452), or number of months in treatment (F £ 1.3; p ³ 0.254). Conversely, the 
AUC of pain experienced at the teeth was significantly influenced by details of what was 
performed at the orthodontic adjustment visits. This applied to both the AUC for current 
pain (F=2.9; p= 0.028) and pain after gum chewing (F=6.0; p<0.001) (Figures 3.2 and 3.3).  
 
There was greater total current (resting) pain at the teeth when comparing “new bond-
ups in at least one arch” to “no arch wire changes +/- bends placed in the arch wire” (p = 
0.009). There were no other statistically significant differences in the total amount of pain 
experienced at the teeth when comparing the other details of adjustment appointments. 
Similarly, there was a statistically significant difference in the total amount of pain 
experienced at the teeth after gum chewing when “new bond ups in at least one arch” 
were compared to “no arch wire changes +/- bends placed in the arch wire” (P < 0.001). 
There were no other statistically significant differences in the total amount of pain 
experienced at the teeth after chewing gum, when comparing the other details of 
































































Figure 3.2 Total amount of current (resting) pain experienced at the teeth when compared to what was performed at the adjustment 



















































	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	            
         
Figure 3.3 Total amount of pain experienced at the teeth after chewing gum when compared to what was performed at the adjustment 




This longitudinal prospective study utilised an EMA approach using a smartphone 
application to investigate orthodontic pain profile following an orthodontic adjustment. In 
general, pain steadily increased following the adjustment, peaked at 8am on day two, and 
then gradually returned toward baseline levels by day four. This pain profile is similar to 
those reported in previous studies (Ngan et al., 1989; Jones and Chan, 1992). 
 
Our findings indicate that using an EMA approach via smartphones is an effective method 
of assessing pain because it allows measurements to be completed at each intended time 
point. Indeed, pain surveys were filled on average 21 minutes after the scheduled time. In 
addition, participants were unable to look at their past pain scores, thereby reducing the 
risk of bias while rating their current pain scores. 
 
One weakness of this study was the relatively small sample size (82 participants). When 
analysed by details of the actual adjustments, the smallest category only included five 
participants. Another weakness was the fact that the use of pain relief could have affected 
the VAS pain scores of the participants. Unfortunately, we did not have time to conduct a 
statistical analysis that could have adjusted for the effects of pain relief on the pain scores. 
Participates who used pain relief were not excluded from the statistical analysis. Therefore, 
we have simply described the proportion of patients in our sample who took analgesics 
during the study period. In addition, the study participants were treated by a number of 
different clinicians. We failed to control for “operator bias” in our statistical analysis. A 
further shortcoming of this study is that we used a VAS that was only 93.5 mm long. It is 
possible that VAS’s shorter than 100 mm may not be as accurate at reporting pain levels 
(Revill et al., 1976). In the future, this issue may be addressed by using a smartphone or 
tablet with a larger screen, so that a 100 mm long VAS can be used. An important strength 
of this study was the use of a smartphone application to collect data and minimise the 
number of pain surveys that were missed. Indeed, 93.6% of the pain surveys were 
completed, with only 6.4% of pain surveys not filled in.  
 
Pain on chewing gum was significantly higher than resting pain at the teeth. The peak pain 
when chewing gum was 36.8% at 8am on day two, while the peak resting pain at the teeth 
was 26.5% at 8am on day two. The gum that was issued was soft in texture, so it would 
not be unreasonable to expect that chewing food of harder consistencies would cause 
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significantly more pain. Two studies have demonstrated that chewing gum may reduce the 
amount of pain after bond-up with fixed appliances and may also reduce the consumption 
of ibuprofen following bond-up (Benson et al., 2012; Ireland et al., 2016). Because we 
wanted to use the gum to elicit chewing discomfort (and not for its potential pain relief 
properties), we asked the participants to avoid chewing it except for when the app asked 
them to (two times per day, twenty chews per occasion).  
 
This study found that gender does not affect the magnitude of orthodontic pain. This finding 
is consistent with the vast majority of studies on orthodontic pain which have not 
demonstrated any sex-related differences (Ngan et al., 1989; Jones and Chan, 1992; 
Fernandes et al., 1998; Sergl et al., 1998; Erdinc and Dinçer, 2004; Scott et al., 2008; 
Abdelrahman et al., 2015; Rahman et al., 2015). By comparison, only a few studies have 
found females to experience greater levels of orthodontic pain (Scheurer et al., 1996; 
Bergius et al., 2002). 
 
Despite there being no consensus regarding the effects of age on pain perception in the 
orthodontic literature, this study found that age has no relationship with the severity of 
pain experienced during orthodontic treatment, which agrees with a number of studies 
(Ngan et al., 1989; Scott et al., 2008; Abdelrahman et al., 2015; Rahman et al., 2015). Some 
authors believe it is hard to assess the relationship between age and pain perception 
because adolescents and adults may be treated with different protocols. One reason this 
study may not have detected a difference is because the age range was limited (10.8 to 
18.2 years), and the treatment protocols and philosophies were quite similar between all 
of the participants.  
 
This study also investigated the effect of  time in treatment on pain severity, and found no 
association. As far as we are aware, no previous study has tested the effect of time in 
treatment and the severity of orthodontic pain. Nonetheless, there was a statistically 
significant association between details of the orthodontic adjustment and the severity of 
pain experienced. Patients who had just been bonded up experienced significantly more 
total resting pain at the teeth, and significantly more total chewing pain at the teeth in the 
three days after bond-up, when compared to patients who had no arch wire changes, with 
or without minor bends placed in the arch wires. It is possible that patients who had just 
been bonded up could have been stressed by the use of cheek retractors and the long 
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appointment time of the bond-up. In addition, oral lesions and ulcers may have caused 
significant pain in the first few days after bond-up. However, this should not have had any 
bearing on our results as the app clearly asks about pain at the teeth, and not about pain 
at the cheeks or soft tissues. Furthermore, given that we didn’t collect pain data from 
participants throughout their entire course of orthodontic treatment, it may be incorrect 
to state that bond-ups caused more pain than other orthodontic adjustments. This could 
easily be addressed in further research by collecting pain data from participants over the 
entire course of their orthodontic treatment, which has never been done before. This is 
the first study that has investigated the association between orthodontic pain, time in 
treatment and details of the adjustment. Accordingly, our findings cannot be compared to 
those from previous studies. 
 
In conclusion, EMA is a promising approach for investigating the effects of multiple factors 
on orthodontic pain in real-world settings.  Peak pain at the teeth occurred approximately 
19 hours after the orthodontic adjustment, and decreased steadily toward baseline levels 
after three days. Gender, age and treatment duration were not associated with the severity 
of pain at the teeth. However, patients undergoing bond-ups experienced significantly more 
pain at their teeth when compared to patients having no arch wire changes, with or without 




4. Genetic factors associated with orthodontic pain in children 
and adolescents  
	
4.1 Introduction 
The perception of pain is an incredibly complex process which is influenced by many 
environmental and genetic factors (Mogil, 1999). In recent times, there has been increasing 
interest in the role of genetic factors which influence pain perception. To date, no studies 
have investigated whether there are associations between certain genetic polymorphisms 
and the intensity of pain experienced by patients undergoing orthodontic treatment. 
However, there is ample evidence that several single nucleotide polymorphisms (SNPs) 
influence the severity of pain caused by fibromyalgia and experimental pain, and can even 
contribute to temporomandibular disorders (TMD).  
 
One of the most commonly studied genes in pain research is the Catechol-O-
methyltransferase (COMT) gene. The COMT gene is located on the long arm of 
chromosome 22, and encodes the COMT enzyme, which is responsible for catalysing the 
degradation of catecholamines such as dopamine, adrenaline and noradrenaline. These 
neurotransmitters are involved in a vast array of physiological processes such as cognition, 
cardiovascular function, stress response, and pain processing (Belfer and Segall, 2011). 
COMT is especially involved in the regulation of extracellular catecholamine concentrations 
in the prefrontal region of the brain. Catecholamines are essential components of both the 
ascending and descending pain tracts, and any changes in catecholamine levels may increase 
or decrease nociception. Interestingly, variations in the level of COMT activity result in 
compensatory effects within the central nervous system. Subjects with low COMT activity 
experience reduced analgesia by endogenous opioids via µ-opioid pathways (Zubieta et 
al., 2003).  
 
The COMT gene locus contains numerous single nucleotide polymorphisms with minor 
allele frequency greater than 1%1. Most of these SNPs are located in noncoding regions, or 
if they are located in coding regions, do not alter the amino acid sequence of the COMT 





significant effects on processes such as DNA transcription, RNA splicing, mRNA stability, 
as well as mRNA transport and translation (Andersen and Skorpen, 2009). Genetic 
variation in the COMT gene has been associated with a number of pain conditions. These 
include differences in pain perception caused by experimental pain stimuli (Zubieta et al., 
2003; Diatchenko et al., 2005), and variable susceptibility to common pain conditions such 
as fibromyalgia (Gursoy et al., 2003; Vargas-Alarcon et al., 2007), migraines (Emin Erdal et 
al., 2001) and temporomandibular disorders (Diatchenko et al., 2005). It is also worth 
noting that numerous splice variants of the 1.5kb COMT transcript have been found in the 
human brain (Tunbridge et al., 2007). At this point in time, the functional significance of 
these splice variants is unknown, but the detection of their presence adds further 
complexity to COMT biology.  
 
Numerous studies have investigated the association between genetics and experimental 
pain and TMD. These probably represent the closest models that we have when beginning 
to investigate the role of genetics on orthodontic pain. Several haplotypes, which refers to 
a set of SNPs on one chromosome inherited together, have been linked to experimental 
pain. The three most common COMT haplotypes are termed high pain sensitivity (HPS), 
average pain sensitivity (APS), and low pain sensitivity (LPS). The four SNPs of the COMT 
gene that contribute to these COMT haplotypes include rs6269, rs4633, rs4818 and 
rs4680. These COMT haplotypes were categorized according to their association with 
sensitivity to experimental pain in humans. Some 11% of the variation in perception of 
experimental pain could be attributed to combinations of these three common haplotypes 
(Diatchenko et al., 2005). Further research has focused on the role of these COMT 
haplotypes on the incidence of TMD in a three-year prospective study containing 202 
women. Females who had only HPS and/or APS haplotypes had a 2.3-fold greater risk of 
developing TMD when compared to females who had one or two LPS haplotypes 
(Diatchenko et al., 2005).  
 
Genetic markers such as SNPs, or combinations of SNPs, are important because they 
implicate enzymes and shed light on the mechanisms behind the aetiology of pain. In 
addition, they also enable us to study gene-environment interactions, whereby an 
environmental influence on disease is only expressed in people with a specific genotype 
(Khoury, 1998). For example, an environmental factor such as depression could be a risk 
factor for TMD among patients with a certain combination of alleles for a SNP. However, 
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depression may not be a risk factor for TMD among patients with differing combinations 
of alleles for this SNP. It is possible that orthodontic treatment with fixed appliances may 
act as an environmental risk factor in the development of TMD. In patients with pain-
sensitive haplotypes of the COMT gene, eight out of 36 patients with a history of 
orthodontic treatment developed TMD during a three-year period. However, none of the 
20 patients with pain-sensitive haplotypes who didn’t have a history of orthodontic 
treatment developed TMD during these three years. This was statistically significant (p = 
0.04). Thus, orthodontic treatment may increase the risk of developing TMD in patients 
with pain-sensitive haplotypes of the COMT gene – this represents a gene-environment 
interaction. In patients with pain-resistant haplotypes, orthodontic treatment was not 
associated with an increase in risk of developing TMD (Slade et al., 2008). 
 
The OPPERA project carried out a large case-control study in America. Some 348 patients 
were affected by chronic TMD, while 1612 control patients were included. 3295 SNPs 
from 358 genes implicated in human pain perception were tested for all of these patients. 
Nine SNPs from six different genes were associated with TMD. These included the 
rs2963155, rs9324918 and rs33389 SNPs of the NR3C1 gene, the rs9316233 SNP of the 
HTR2A gene, the rs7800170 SNP of the CHRM2 gene, the rs3756612 and rs10491334 
SNPs of the CAMK4 gene, the rs728273 SNP of the IFRD1 gene, and the rs12415832 
SNP of the GRK5 gene (Smith et al., 2011). This study also tested the association between 
COMT haplotypes and TMD. Participants with HPS haplotypes had an increased risk of 
TMD (OR = 1.28, p = 0.05). Interestingly, there was no significant difference between the 
APS and LPS haplotypes in their case-control study.  
 
A smaller case-control study conducted in Italy recruited 50 patients affected by TMD and 
132 controls. The entire COMT gene was sequenced for all participants. 40 COMT variants 
were found, 18 of which were novel discoveries. The SNPs rs1655656, rs165722 and 
rs4646310 were found significantly more frequently in TMD patients when compared to 
the controls. All of these SNPs are located in the promoter region of the COMT gene. 
The SNPs rs1655656 and rs4646310 were novel - patients with the CC genotype of 
rs1655656 were 5.3 times more likely to suffer from TMD when compared to the patients 
with the GG genotype, while patients with the AG genotype of rs4646310 were 2.6 times 
more likely to suffer from TMD when compared to patients with the GG genotype 
(Michelotti et al., 2014). It is proposed that the SNPs located in the promoter region of 
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the COMT gene could alter DNA transcription, RNA splicing, mRNA stability, or mRNA 
transport and translation (Nackley et al., 2006), ultimately leading to an increased risk of 
TMD. Interestingly, this study did not test the effect of the three most common COMT 
haplotypes, as mentioned previously, on the risk of TMD.   
 
Given that patients with pain-sensitive haplotypes of the COMT gene perceive higher 
intensities of pain during experimental pain studies, as well as having an increased risk of 
developing TMD, it is plausible that these same patients could also experience more pain 
during orthodontic treatment with fixed appliances. Therefore, our aims were 
to determine whether certain SNPs/haplotypes of the COMT, HTR2A and NR3C1 genes 
are associated with the severity of orthodontic pain experienced by patients undergoing 























The study utilised a longitudinal prospective design, which was developed according to the 
STROBE guidelines (von Elm et al., 2007). The study was set between June 2016 and April 
2017 and was based in the orthodontic clinic at the Faculty of Dentistry, University of 
Otago, New Zealand. 
 
A convenience sample of 82 orthodontic patients who fulfilled the inclusion and exclusion 
criteria were recruited (see Chapter 2 for more details about the recruitment process).  
	
4.2.1 DNA collection 
Participants were asked to provide a DNA sample in the form of blood or saliva. Blood 
was encouraged, as it contains a greater quality and quantity of DNA when compared to 
saliva.  A registered nurse collected blood samples on-site using standard venepuncture 
procedures. The samples included a 10 mL EDTA tube that was used for DNA preparation, 
and a 5 mL gold top SST tube for serum. The SST vacutainers were centrifuged at 3,500 
rpm on-site, and then taken to the Merriman Laboratory (University of Otago) for storage. 
When venepuncture was refused, 10 mL of saliva was collected instead, using specific saliva 
kits (DNA genotekTM Oragene-500 kits).  
	
4.2.2 DNA extraction 
The DNA was extracted using a chloroform extraction with an ethanol precipitation 
method on whole blood (buccal cells for saliva).  
4.2.3 Candidate gene and SNP selection 
Selected SNPs from the COMT (rs6269, rs4680, rs4646310), NR3C1 (rs2963155) and 
HTR2A (rs9316233) genes were selected after a review of the literature. Please see Table 
1.3 in Chapter 1, which highlights some of the pain conditions that these SNPs have been 
associated with. 
4.2.4 Genotyping         	
Genotyping of the above SNPs was conducted using TaqMan SNP genotyping assays (from 
Thermo Fisher; 5 Caribbean Dv, Scoresby, VIC 3179, Australia) in conjunction with KAPA 
Probe Fast Master mix on a Lightcycler 480 real-time PCA machine. Genotyping was 




4.2.5 Assessing pain outcomes 
Immediately following an orthodontic adjustment appointment, regardless of the stage of 
treatment that they were in, the participants were issued with an Android smartphone 
(Vodafone Smart Prime 6, with a 5” colour display). They then filled out regular pain surveys 
in the first three days after their fixed appliances were adjusted (please refer back to 
Chapters 2 and 3 for more details)  
	
4.2.6 Statistical analysis 
Data were analysed using conventional descriptive methods. One-Way ANOVA was used 
to assess differences in pain severity across genotypes and haplotypes. Analyses were 
carried out using the Statistical Package for the Social Sciences (SPSS v22.0, SPSS Inc, 
Chicago IL, USA), and Stata (version 13.1; Stata Corp LP, College Station, TX, USA). 















The various SNP genotypes and mean pain values experienced at the teeth are presented 
in Table 4.1. Participants with the AA genotype of the rs4646310 SNP of the COMT gene 
experienced almost triple the total resting (current) pain at the teeth compared to the AG 
and GG genotypes (p = 0.022). In addition, participants with the CG genotype of the 
rs9316233 SNP of the HTR2A gene experienced almost double the total chewing pain at 
the teeth when compared to those with the CC and GG genotypes (p = 0.018). The 
remainder of the SNPs did not show statistically significant differences in pain at rest 











Resting pain  
at T3 (Peak) 
Chewing pain  
at T3 (Peak) 
Resting pain  
T0 – T7 (Overall) 
Chewing pain  
T0 – T7 (Overall) 
rs6269 (COMT) 	 	 	 	 	
  AA 32 (40) 28.3 ± 23.1 41.8 ± 27.8 111.9 ± 86.4 192.1 ± 120.0 
  AG 41 (51.25) 24.6 ± 25.6 33.1 ± 32.4 109.6 ± 115.1 176.0 ± 156.7 
  GG 7 (8.75) 21.3 ± 20.6 25.1 ± 23.1 69.3 ± 51.2 103.7 ± 76.7 
rs4680 (COMT)      
  AA 23 (29.87) 28.2 ± 24.3 37.9 ± 28.4 100.9 ± 68.3 169.5 ± 102.7 
  AG 41 (53.25) 23.8 ± 24.3 34.8 ± 31.7 109.7 ± 114.7 184.8 ± 159.0 
  GG 13 (16.88) 30.3 ± 23.9 36.9 ± 27.2 110.5 ± 93.2 169.8 ± 124.6 
rs4646310 (COMT)      
  AA 1 (1.28) 63.0 ± NA 64.0 ± NA 366.0 ± NAa 349.0 ± NA 
  AG 30 (38.46) 20.6 ± 19.8 32.1 ± 30.5 93.6 ± 82.7 156.4 ± 136.1 
  GG 47 (60.26) 29.4 ± 25.6 39.0 ± 29.7 114.1 ± 104.0 190.8 ± 138.5 
rs2963155 (NR3C1)      
  AA 43 (54.43) 23.3 ± 24.1 32.4 ± 30.5 96.9 ± 94.7 167.0 ± 143.8 
  AG 32 (40.51) 28.1 ± 24.1 40.4 ± 30.5 114.1 ± 102.7 187.7 ± 135.9 
  GG 4 (5.06) 28.8 ± 26.3 32.3 ± 25.1 149.8 ± 152.0 162.3 ± 132.7 
rs9316233 (HTR2A)      
  CC 47 (59.49) 23.4 ± 23.7 29.6 ± 28.3 86.3 ± 78.0 140.0 ± 108.4b 
  CG 30 (37.97) 29.1 ± 24.7 44.0 ± 30.2 134.3 ± 120.5 229.4 ± 162.6 
  GG 2 (2.53) 23.5 ± 30.4 37.5 ± 46.0 93.5 ± 101.1 138.5 ± 146.4 
a P = 0.022, b P = 0.018 
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The mean chewing pain at T3 (peak pain during the three-day observation period) is 
plotted against the COMT haplotypes in Figure 4.1. The greatest chewing pain was 
observed in participants with the APS/HPS and HPS/LPS haplotypes, while the lowest pain 
was observed in those with the LPS/LPS haplotype. However, there was no significant 



































































Figure 4.2 is very similar to Figure 4.1, but shows the mean total chewing pain over three 
days against the COMT haplotypes. Once again, the greatest chewing pain was observed 
in participants with the APS/HPS and HPS/LPS haplotypes, while LPS/LPS experienced the 

















































































Figure 4.2 Mean total reported pain score after chewing by different COMT haplotypes (T0-T7; overall). Error bars represent standard error. 
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Figure 4.3 from the work by Diatchenko and colleagues (2005) demonstrates that the 
APS/HPS haplotype was associated with the greatest experimental pain sensitivity, while 
LPS/LPS was associated with the lowest experimental pain sensitivity. When comparing 
Figures 4.1, 4.2 and 4.3, it can be seen that there is a similar gradient between the COMT 
haplotypes and the severity of pain experienced. The APS/HPS haplotypes experienced 
the greatest amount of orthodontic and experimental pain, the LPS/LPS haplotypes 
experienced the least amount of orthodontic and experimental pain, while the other three 















































P = 0.0004 




This is the first study to investigate the role of genetic influences on the intensity of pain 
following the adjustment of orthodontic fixed appliances. Since previous studies have not 
investigated the role of genetics on orthodontic pain, genes implicated in TMD were used 
to test for this association.  
 
The main weakness of this study was the small sample size (82 participants). In genetic 
research, large sample sizes are required, as genes often only show minor effects. However, 
this weakness will be addressed in the future as we increase our study sample. The aim is 
to recruit 300 participants, which will greatly enhance the statistical power to detect 
common genetic variants with minor effects. Another weakness is the subjective nature of 
the VAS used to assess pain severity. This is not just a shortcoming of the VAS, but a 
weakness of all available instruments since the perception of pain is largely subjective. In 
addition, approximately 10 subjects had to be excluded from this study because we could 
not analyse the DNA from their saliva samples. The only way to ensure high-quality DNA 
is through blood sampling, which not all study participants were happy to provide. The 
strengths of this study include the use of a specialized smartphone app, which ensured that 
the pain data collected was reliable. The latter is important since reported pain scores can 
be inaccurate if patients fill them in retrospectively. In addition, participants were unable to 
look at their past pain scores, thus reducing any bias or error when it came to recording 
their current pain scores.  
 
There was a statistically significant difference in the total amount of chewing pain at the 
teeth for the rs9316233 SNP of the HTR2A serotonin 2A receptor gene. Participants with 
the CG genotype experienced significantly more total chewing pain at the teeth in the first 
three days after the adjustment of their fixed appliances when compared to participants 
with the CC and GG genotypes. This finding would also be considered clinically significant, 
as the patients with the CG genotype experienced approximately 64% more pain on 
chewing than the CC and GG genotypes in the three days after adjustment of their fixed 
appliances. The rs9316233 SNP is an intronic polymorphism of the HTR2A gene. In the 
OPPERA study, the minor G allele was protective against TMD (OR = 0.64). Interestingly, 
the effect of this SNP applied only to females, and was not observed in males. For white 
females alone, the protective effect of the minor G allele was even more pronounced (OR 
= 0.39, P = 2.3 x 10-4). In addition, there seemed to be a race-specific effect, with no effect 
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seen in African Americans (OR = 0.9, P = 0.77). For non-Hispanic whites, the OR was 
0.56, P = 0.0053 (Smith et al., 2011). However, this race-specific effect would have had 
minimal influence on the present study, as the vast majority of participants identified as 
being New Zealand Caucasian. Interestingly, the G allele was not protective against pain in 
this study, with the CG genotype associated with the most pain. The genetic analysis was 
completed for both males and females together, so it is unclear whether a gender-based 
effect exists in our sample.  
 
The rs6313 SNP of the HTR2A gene, a synonymous polymorphism in the first exon, has 
also been associated with TMD in another study (Mutlu et al., 2004). The rs6313 SNP lies 
40kb upstream from the rs9316233 SNP, and the two SNPs are not in strong linkage 
disequilibrium (D’ = 0.29, r2 = 0.02). A more recent prospective cohort study identified 
two SNPs (rs12584920 and rs17289394) of the HTR2A gene associated with chronic 
widespread musculoskeletal pain (Nicholl et al., 2011). This gene has been implicated in 
influencing both nociceptive and affective pathways (Slade et al., 2016), which suggests that 
it is biologically plausible for the rs9316233 SNP to affect the total amount of chewing pain 
at the teeth in our study.  
 
There was also a statistically significant difference in the total amount of resting (current) 
pain at the teeth for the rs4646310 SNP of the COMT gene. The AA genotype (366 total 
pain units) experienced significantly more total pain at the teeth when compared to the 
AG (93.6 total pain units) and GG (114.1 total pain units) genotypes. However, there was 
only one participant who had the AA genotype. In addition, this participant underwent a 
bond-up, which we have shown produces the highest levels of pain compared to any other 
orthodontic adjustment. Therefore, larger sample sizes would be required to investigate 
this association further. 
 
This study also investigated the role of COMT haplotypes on pain caused by fixed 
appliances. These were not significantly associated with pain severity in this study. However, 
there was a distinct pattern evident – the APS/HPS haplotypes experienced the greatest 
total amount of chewing pain, while the LPS/LPS haplotypes experienced the least pain. 
This is consistent with the findings of Diatchenko and colleagues (2005), who found that 
females with the APS/HPS haplotypes were 2.3 times more likely to develop TMD when 
compared to females who had one or two LPS haplotypes. We did not analyze our data 
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by gender, as males and females showed a similar amount of pain at the teeth after their 
fixed appliances were adjusted. Even though the differences in perceived pain between the 
two haplotypes were not statistically significant, they are arguably clinically significant. 
Indeed, participants with the HPS/APS haplotypes experienced 2.4 times more pain at their 
teeth than the LPS/LPS haplotypes.  
 
It has been shown that the different haplotypes of the COMT gene do not lead to 
differences in the amount of COMT mRNA. This suggests that the differences in enzymatic 
activity are a result of differences in protein translation – the LPS haplotype results in 
COMT activity which is 4.8 times higher than that of the APS haplotype, while the LPS 
haplotype results in COMT activity 11.4 times higher than the HPS haplotype. One theory 
for this effect is that interactions between the rs4633, rs4818 and rs4680 SNPs result in 
changes of the mRNA secondary structure, which ultimately affects the efficacy of protein 
translation (Diatchenko et al., 2005). However, it is unclear as to how differences in COMT 
activity affect pain perception. Reduction in COMT activity associated with a met allele at 
codon 158 has been shown to decrease levels of endogenous opioids in certain regions of 
the CNS, leading to increased pain (Zubieta et al., 2003). Additionally, reduced COMT 
activity could result in increased levels of catecholamines such as adrenaline, leading to 
persistent pain states through stimulation of B2-adrenergic receptors in both the CNS and 
PNS (Khasar et al., 2003).  
 
Findings from this preliminary study are promising, and include important associations 
between orthodontic pain and the rs9316233 SNP of the HTR2A gene and the rs4646310 
SNP of the COMT gene. In addition, there was some evidence of a pattern for orthodontic 
pain across haplotypes of the COMT gene, even though this did not reach statistical 
significance. In the future, it will be interesting to investigate these associations further using 
a larger sample size. In summary, certain SNPs and haplotypes of the HTR2A and COMT 
genes appear to play some role in the severity of orthodontic pain following the adjustment 




5. Future directions and conclusions 
	
This research utilised an EMA approach using a smartphone app to measure pain at the 
teeth in the three days after an orthodontic adjustment. We believe that this is currently 
the most accurate and reliable method of measuring orthodontic pain. Further research 
could assess pain after every adjustment of participants’ fixed appliances, which would 
certainly provide greater insight into the pain profiles of orthodontic patients as treatment 
progresses. In addition, this method has the potential to be very useful in measuring other 
forms of pain, such as TMD and headaches. Measuring pain in real-time should be much 
more accurate and reliable when compared to retrospective pain reports.  
 
This study found exciting associations between the rs9316233 SNP of HTR2A gene, the 
rs4646310 of the COMT gene, and the severity of pain after an orthodontic adjustment. 
In addition, there were promising associations between haplotypes of the COMT gene and 
the severity of orthodontic pain. Our aim is to significantly increase the sample size over 
the next two years. In the future, with reducing costs of genetic testing, it may be possible 
to perform genome-wide testing on a larger sample which would help uncover novel 
associations between common genetic polymorphisms and orthodontic pain.  
 
If there is a genetic influence on the severity of pain following the adjustment of orthodontic 
appliances, routine saliva samples of all our patients could identify those who are likely to 
experience higher levels of pain and discomfort. This paves the way towards personalised 
medicine. We may be able to tailor our treatment to minimise pain for these susceptible 
individuals. For example, clinicians may consider increasing the time between successive 
adjustment appointments, preparing patients and their parents psychologically, using 
materials with different force properties, and providing individualised pain relief protocols. 
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Date:		 	 	 	 ____/____/____	 	
	 	
ID:		 	 	 	 ______________	
	








• Previous	archwire	(Mx)	 	 __________	
• Previous	archwire	(Md)	 	 __________	
• New	archwire	(Mx)	 	 	 __________	
• New	archwire	(Md)	 	 	 __________	
• Time	and	date	of	archwire	change	 __________	
• FULFA	 	 	 	 	 Yes/No	





• Have	access	to	an	Android	smartphone	 	 	 Yes/No	
• Craniofacial	syndromes	such	as	cleft	lip	and	palate	 	 Yes/No	
• Anxiety	disorders	or	depressive	illness	 	 	 Yes/No	
• Chronic	pain	syndromes	 	 	 	 	 Yes/No	
• Use	of	neurologically-acting	medication	 	 	 Yes/No	
• Active	decay	or	gum	disease	 	 	 	 	 Yes/No	
• Are	you	less	than	18	years	of	age?	 	 	 	 Yes/No	
• Previous	history	of	orthodontic	treatment	(before	current	braces)	 	 	
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7.3 Flow of “My Braces Experience” app 
	




Figure 1.  
Participants are sent to WSH as soon as 
they have finished getting their braces 
adjusted by their orthodontic postgraduate 
student.  
 
The participant’s user ID, first name, last 
name and date of birth are entered. 
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	








	 	 	 	 	 	 Figure 2.  
      Scroll to the bottom of this screen, then 
      enter the participant’s sex (male or  











Figure 3.  
      Some information about this research 
      project is provided for participants. NB, 
      we changed the inclusion criteria to  
      include any adjustment of the braces  
      (as including only patient’s having arch 
      wire changes would have reduced the 
      number of participants that we could  
      collect data from during the limited  




















	 	 	 	 	 	
	 	 	 	 	 	 Figure 4.  
      This screen is no longer relevant, as  
      participant’s do not need to have had an
      arch wire change to be eligible to start 
      this app. The text should really read, “Has 
      your orthodontist confirmed that you 
      have just had your braces adjusted?”. 
      Participants can then select “no” or “yes”. 
      The app will not let participants proceed 








	 	 	 	 	  Figure 5.  
More information for the participants. 















	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	






	 	 	 	 	 	 	 	
Figure 6.  
      The first question asks about  
      consumption of pain relief. “No” or “Yes”





















	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 Figure 7.  
If “Yes” is selected, participants can select 




































Figure 8.  
Using a visual analogue scale, participants are asked to describe the current pain 
level at their teeth. The pointer can be moved anywhere along the horizontal line 


















Figure 9.  

















	 	 	 	 	 	 Figure 10.  
      This question asks participants about pain 
      in the jaw, temple, in the ear, or in front 
      of the ear. Participants can select “No” or 
      “Yes” in response to this question.  

















	 	 	 	 	 	
	 	 	 	 	 	 Figure 11. 
      If “Yes” was selected, participants can  
      select what site and what side they have 

























	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 Figure 12.  
      As an example, this participant has  
      experienced pain in the jaw region on the 
      left side. 


























Figure 13.  















	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	
	 	 	 	 	 	 Figure 14.  
This question asks participants about 
headaches that include the temple areas of 
the head. Participants can answer “No” or 
















	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	
Figure 15.  
If “Yes” was selected, participants can select 



























	 	 	 	 	 	 Figure 16.  
      As an example, this participant  
      experienced headache pain in the right 























Figure 17.  
In terms of headache pain, this patient experienced the “worst pain imaginable” at 
























Figure 18.  






















Figure 19.  


















	 	 	 	 	 	 Figure 20.  
      This screen alerts participants that their 



















	 	 	 	 	 	
	 	 	 	 	 	 Figure 21.  
      At 8pm on the first day, the application 
      will play an audio alert to inform the  
      participant that the second survey is  
























Figure 22.  
Again, participants are asked about pain
   relief consumption. However, from the 
   second survey onwards, the survey asks 
   about pain relief consumption in the  
   previous 12 hours (the first survey asks 
   about pain relief consumption in the  






















Figure 23.  


























Figure 24.  
This question is not included in the first survey. It asks participants about the 










	 	 	 	 	  Figure 25.  
      Once again, participants are asked about 
      pain in the jaw, temple, in the ear, or in 
      front of the ear. Participants can select 
      “No” or “Yes” in response to this  























	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 Figure 26.  
      As an example, this participant has  
      experienced pain in front of the ear on 




























Figure 27.  
This patient is experiencing the “worst pain imaginable” in front of his/her ear on 



























Figure 28.  
This question is not included in the first survey. It asks participants about the 









	 	 	 	 	 	 Figure 29.  
Once again, participants are asked about 
headaches that include the temple areas of 
the head. Participants can answer “No” or 
























	 	 	 	 	 	 Figure 30.  
      As an example, this participant  
      experienced headache pain in the left 


























Figure 31.  
In terms of headache pain, this patient is experiencing the “worst pain imaginable” 



























This question is not included in the first survey. It asks participants about the 



















Figure 33.  




























Figure 34.  









	 	 	 	 	 	 Figure 35.  
      This screen alerts participants that their 
      next survey is tomorrow at 8am. At the 
      subsequent surveys, figures 21-35 are  
      repeated. All in all, participants fill in 7 















































Manager, Academic Committees, Mr Gary Witte
H15/124
Professor M Farella
Department of Oral Sciences
Faculty of Dentistry
Dear Professor Farella,
I am again writing to you concerning your proposal entitled “Genetic and psychological
factors associated with orthodontic pain”, Ethics Committee reference number H15/124.
Thank you for your e-mail of 10th February 2016, with attached revised documentation,
addressing the issues raised by the Committee.
On the basis of this response, I am pleased to confirm that the proposal now has full ethical
approval to proceed.
The standard conditions of approval for all human research projects reviewed and approved
by the Committee are the following:
Conduct the research project strictly in accordance with the research proposal submitted and
granted ethics approval, including any amendments required to be made to the proposal by
the Human Research Ethics Committee.
Inform the Human Research Ethics Committee immediately of anything which may warrant
review of ethics approval of the research project, including: serious or unexpected adverse
effects on participants; unforeseen events that might affect continued ethical acceptability of
the project; and a written report about these matters must be submitted to the Academic
Committees Office by no later than the next working day after recognition of an adverse
occurrence/event. Please note that in cases of adverse events an incident report should also
be made to the Health and Safety Office:
http://www.otago.ac.nz/healthandsafety/index.html
Advise the Committee in writing as soon as practicable if the research project is discontinued.
Make no change to the project as approved in its entirety by the Committee, including any
wording in any document approved as part of the project, without prior written approval of the
Committee for any change. If you are applying for an amendment to your approved research,
please email your request to the Academic Committees Office:
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This	 research	project	will	help	 to	 improve	our	understanding	of	orthodontic	pain,	and	may	enable	

























































where	 the	blood	 is	withdrawn.	Although	very	 rare,	 this	 site	may	become	 infected.	However,	most	
people	have	no	problems	from	this	routine	procedure.	If	you	have	had	any	bad	experiences	with	giving	
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Genetic and Psychological Factors Associated with Orthodontic 
Pain 
 
Information sheet for child participants 
 
Thank you for agreeing to consider helping us out. This sheet will explain to you what 
we are trying to do, and help you to decide whether or not to participate. In either case, 
we thank you for considering our request. Please remember, there is nothing wrong 
with not participating if that’s what you prefer.  
 
What are we trying to do?  
Braces can be painful sometimes, especially in the first few days after an orthodontist 
has adjusted them. We are trying to find out whether certain genes, or the way we 
think, can influence the amount of pain caused by braces. This could eventually help 
orthodontists to reduce the amount of pain that their patients have to endure.  
 
Who are we looking for?  
We are looking for volunteers who currently have braces, and volunteers who are 
about to receive braces.  
 
What will you be asked to do?  
We need three things from you – something to extract the DNA from, information about 
the way you think, and information about the pain you have experienced after you 
have had your braces adjusted.  
 
Your DNA, which contains the genes we want to study, is found either in blood or 
saliva. We would like to take a very small sample of your blood to extract this DNA. 
This will involve you visiting a nurse who will do this for you. We prefer the DNA that 
we get from your blood as it helps us a lot more, but we can also collect some saliva 
instead, if you really don’t want to give blood. Saliva samples involve spitting some of 
your saliva into a small tube. We will only need to collect your DNA once (either 
through blood or saliva). If you have already given us blood or saliva as part of an 
existing research project within the orthodontics department, we will not require any 








The second part involves you answering some questions about the way you think. The 
total time to collect the DNA and fill in the questionnaires should take about 30-45 
minutes.  
 
Finally, we will ask you to record the amount of pain you are feeling in the three days 
after adjustment of your braces. You can enter the amount of pain you are feeling on 
your smartphone. Each time you are asked to record the amount of pain you are 
feeling, you will also be asked to chew on some chewing gum, and record the amount 
of pain caused by the chewing.  
 
What will we do with your information?  
We will use your DNA sample and other information you have given us to learn more 
about orthodontic pain caused by braces. Your DNA sample will be stored and tested 
in Associate Professor Merriman’s laboratory at the University of Otago. We will keep 
this information for at least 10 years. Please note that we may use the information 
collected from this research project for future related research projects. However, all 
information that you have provided to us will be de-identified. 
 
We will write up the results from this study for our university work. The results may 
also be written up in journals and talked about at conferences, but your name will not 
be on anything written up about this study.  
 
Who will see my answers and other bits of information?  
Only the research team and the people we work with will look at the information you 
have kindly given to us.  
 
Can I change my mind and pull out from the project?  
Yes, you can. You may pull out from participation in the project at any time, and without 
any disadvantage to yourself of any kind.  
 
What if I have any questions?  
If you have any questions about what we are doing, either now or in the future, please 
let us know:  
 
William Sew Hoy/Cindy Mullens   Joseph Antoun 
Phone: +64 3 479 7071    Phone: +64 3 479 7071 
Email: sewwi843@student.otago.ac.nz  Email: joseph.antoun@otago.ac.nz 









            
            
            
            
            
            
            
            
            


























7. I	 know	 that	 the	 questionnaires	 will	 explore	 psychological	 factors	 which	 may	 be	
associated	with	orthodontic	pain,	and	that	if	the	line	of	questioning	develops	in	such	


























Tony	 Merriman’s	 laboratory	 for	 at	 least	 ten	 years.	 I	 also	 understand	 that	 the	






































































6. I	 know	 that	as	a	participant,	my	 child	will	 be	providing	 the	 study	 researchers	with	
information	such	as	his/her	medical	history,	 the	questionnaires	 that	he/she	will	be	
completing,	 the	 DNA	 from	 his/her	 blood/saliva	 sample,	 and	 the	 pain	 scores	 after	
adjustment	of	his/her	braces,	as	listed	in	the	Information	Sheet.		
	
7. I	 know	 that	 the	 questionnaires	 will	 explore	 psychological	 factors	 which	 may	 be	
associated	with	orthodontic	pain,	and	that	if	the	line	of	questioning	develops	in	such	
a	way	that	my	child	feels	hesitant	or	uncomfortable,	he/she	may	decline	to	answer	


















University	 of	 Otago	 Library,	 but	 any	 personal	 identifying	 information	 will	 remain	
























































             
             
      
Genetic and Psychological Factors Associated with Orthodontic Pain 
 
CONSENT FORM for child participants  
 
I have been told about this study and understand what it is about. All my questions have 
been answered in a way that makes sense.  
 
I know that:  
 
1. Participation in this study is voluntary, which means that I do not have to take 
part if I don’t want to, and nothing will happen to me. I can also stop taking part at 
any time and don’t have to give a reason. 
 
2. Any time I want to stop, that’s OK. 
 
3. If I don’t want to answer some of the questions, that’s fine. 
 
4. If I have any worries or if I have any other questions, then I can talk about these 
with the research team. 
 
5. The paper and computer file with my answers will only be seen by the research 
team and the people they work with. They will keep whatever I say private. 
 
6. The research team will write up the results from this study for their university 
work. The results may also be written up in journals and talked about at 
conferences. My name will not be on anything written up about this study. 
 
7. The research team may use the information that I have given for similar research 
projects in the future. I understand that this information will be de-identified and 
will not be able to be traced back to me.  
 




(Signed)        (Date) 
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7.6 Maori consultation  
	
	
	
	
	
	 	
	
	
	
	
	
	
	
	
	
	
	
	
